Inhibiting the palmitoylation of DHHC3 or PD-L1 through pharmacological or genetic methods can reduce the expression of PD-L1 in tumor cells, enhancing the cytotoxic effect of T cells against the tumor. This evidence concerns the gene CD274 and neoplasm.